IIM
CRSP icon

Ipswich Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Ipswich Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Buy
23,798
+265
+1% +$14K 0.27% 79
2026
Q1 		$1.12M Sell
23,533
-1,500
-6% -$79.1K 0.26% 77
2025
Q4 		$1.31M Sell
25,033
-165
-0.7% -$9.88K 0.3% 70
2025
Q3 		$1.63M Buy
25,198
+230
+0.9% +$13.2K 0.38% 61
2025
Q2 		$1.21M Buy
24,968
+425
+2% +$16.4K 0.29% 76
2025
Q1 		$835K Sell
24,543
-745
-3% -$31.6K 0.21% 97
2024
Q4 		$995K Buy
25,288
+750
+3% +$35.4K 0.24% 88
2024
Q3 		$1.15M Buy
24,538
+173
+0.7% +$8.78K 0.27% 79
2024
Q2 		$1.32M Sell
24,365
-480
-2% -$27.8K 0.31% 71
2024
Q1 		$1.69M Buy
24,845
+650
+3% +$46.5K 0.4% 60
2023
Q4 		$1.51M Buy
24,195
+610
+3% +$33.7K 0.38% 61
2023
Q3 		$1.07M Hold
23,585
– – 0.29% 79
2023
Q2 		$1.32M Sell
23,585
-440
-2% -$25K 0.35% 74
2023
Q1 		$1.09M Sell
24,025
-445
-2% -$21.6K 0.3% 81
2022
Q4 		$995K Sell
24,470
-689
-3% -$36.5K 0.28% 85
2022
Q3 		$1.64M Sell
25,159
-820
-3% -$59.4K 0.52% 56
2022
Q2 		$1.58M Sell
25,979
-301
-1% -$17.7K 0.45% 63
2022
Q1 		$1.65M Sell
26,280
-460
-2% -$28.9K 0.41% 71
2021
Q4 		$2.03M Sell
26,740
-720
-3% -$62.9K 0.47% 62
2021
Q3 		$3.07M Buy
27,460
+410
+2% +$51.5K 0.79% 43
2021
Q2 		$4.38M Sell
27,050
-30
-0.1% -$3.65K 1.12% 23
2021
Q1 		$3.3M Sell
27,080
-1,670
-6% -$252K 0.93% 35
2020
Q4 		$4.4M Sell
28,750
-2,680
-9% -$317K 1.32% 19
2020
Q3 		$2.63M Sell
31,430
-7,535
-19% -$668K 0.84% 40
2020
Q2 		$2.86M Sell
38,965
-1,950
-5% -$114K 0.99% 35
2020
Q1 		$1.74M Sell
40,915
-2,325
-5% -$120K 0.68% 47
2019
Q4 		$2.63M Sell
43,240
-485
-1% -$26.5K 0.77% 43
2019
Q3 		$1.79M Sell
43,725
-335
-0.8% -$16K 0.57% 54
2019
Q2 		$2.08M Sell
44,060
-95
-0.2% -$3.8K 0.66% 47
2019
Q1 		$1.58M Sell
44,155
-760
-2% -$26.3K 0.52% 59
2018
Q4 		$1.28M Sell
44,915
-1,490
-3% -$51.8K 0.47% 59
2018
Q3 		$2.06M Sell
46,405
-10,675
-19% -$559K 0.7% 49
2018
Q2 		$3.35M Buy
57,080
+5
+0% +$285 1.54% 24
2018
Q1 		$2.61M Buy
57,075
+8,818
+18% +$364K 1.1% 28
2017
Q4 		$1.13M Buy
+48,257
New +$917K 0.48% 58

Other funds holding CRSP

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SC
Slow Capital Greenbrae, California $857M AUM 38.3% 1-Year Est. Return
CIC
Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $900M AUM
BIP
Bouvel Investment Partners Phoenixville, Pennsylvania $442M AUM 70.77% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
LIM
Leavell Investment Management Mobile, Alabama $2.74B AUM 26.51% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PFGIA
Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return

Ipswich Investment Management's CRSP Position: Q2 2026 in Review

Ipswich Investment Management increased its CRISPR Therapeutics (CRSP) stake by 1.1% in Q2 2026, buying an estimated $14K and bringing the position to 23,798 shares worth $1.3M. The position accounts for 0.27% of the portfolio, ranked #79.

Ipswich Investment Management first reported a position in CRSP in Q4 2017 and has held it in 35 quarters since. The position peaked at $4.4M in Q4 2020. 78 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Ipswich Investment Management held 23,798 shares of CRISPR Therapeutics worth $1.3M as of Q2 2026.
  • Ipswich Investment Management bought 265 CRISPR Therapeutics shares in Q2 2026, an estimated $14K.
  • CRISPR Therapeutics made up 0.27% of Ipswich Investment Management's portfolio in Q2 2026, its #79 holding.
  • Ipswich Investment Management first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 35 quarters since.
  • Ipswich Investment Management's CRISPR Therapeutics position peaked at $4.4M in Q4 2020.
  • 78 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Ipswich Investment Management's 13F filing for Q2 2026, filed 16 Jul 2026.